UC vs. Harvard: Round 2 in CRISPR gene technology fight – Santa Cruz Sentinel
Scientific American |
UC vs. Harvard: Round 2 in CRISPR gene technology fight
Santa Cruz Sentinel It’s a high stakes showdown over intellectual-property rights between two of the nation’s most prestigious institutions, with perhaps a billion dollars in the balance. While research universities often reach settlements over patent disputes, both sides … All You Need to Know for Round 2 of the CRISPR Patent FightScientific American UC vs. Harvard: Round 2 in CRISPR fightThe Mercury News UC fights for CRISPR patent rights against Broad Institute, Harvard …Daily Californian |
Genetic Engineering & Biotechnology News |
Superimmune Cell Lines Courtesy of Synthetic Biology
Genetic Engineering & Biotechnology News Early efforts to recode E. coli were described in 2013, when a Science article (“Genomically Recoded Organisms Expand Biological Functions”) appeared describing how 321 instances of a single redundant codon had been removed from the organism’s genome … Genome writing project aims to rally scientists around virus-proofing cellsScience Magazine Scientists downsize bold plan to make human genome from scratchNature.com “Project Recode” aims to make human cells invulnerable to infectionMIT Technology Review Longview News-Journal all 10 news articles » |
|
T cell biomarker predicts which CLL patients will respond to CAR T cell therapy
Science Daily Penn Medicine researchers may have found the reason why some patients with advanced chronic lymphocytic leukemia (CLL) don’t respond to chimeric antigen receptor (CAR) T cell therapy, and the answer is tied to how primed patients’ immune systems are … |
|
Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics
Endpoints News The progress of Spark and its gene therapy hit Luxturna — along with new partnerships forged by its pharma brethren Pfizer and Novartis — likely laid the groundwork for Roche to reconsider its partnership with 4DMT. Roche and 4DMT’s first … |
|
Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics
Endpoints News The progress of Spark and its gene therapy hit Luxturna — along with new partnerships forged by its pharma brethren Pfizer and Novartis — likely laid the groundwork for Roche to reconsider its partnership with 4DMT. Roche and 4DMT’s first … |